| Symbol
| CCL5
| contributors: mct/npt - updated : 22-02-2016
|
| HGNC name
| chemokine (C-C motif) ligand 5
|
| HGNC id
| 10632
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
|
| --over
|
|
of CCL5 and median chemokine receptor 7 (CCR7) mRNA expression in localized scleroderma lesions as compared to healthy controls  | | constitutional
|
|
| --over
|
| |
in both serum and synovial fluid of rheumatoid arthritis | | tumoral
|
|
| --over
|
| |
in Waldenstrom macroglobulinemia, and CCL5 levels positively correlated with features of disease aggressiveness such as elevated IgM levels and bone marrow involvement | |
| Susceptibility
|
to emphysema in COPD to pulmonary tuberculosis (PTB) to Kawasaki disease (KD) to oral cancer |
| Variant & Polymorphism
SNP
| increasing the risk of emphysema in COPD |
|
SNPs in CCL5-28 and -403 genes could increase the risk to have oral cancer |
|
haplotype A-C-C and the diplotype G/A-T/C may be associated with resistance to PTB |
|
CCL5 -403A variant may be associated with coronary involvement in KD |
|
|
| 
|
Candidate gene
| Marker
| may serve as a useful marker of rheumatoid arthritis activity | |
CCR5 and CCL5 are potential markers for metastatic Pancreatic cancer (PC) cancer | |
| Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| digestive | liver | | |
| successful therapeutic approach to reduce experimental liver fibrosis by antagonizing CCL5 receptors | | cancer | hemopathy | | |
| a potential target for the treatment of Waldenstrom macroglobulinemia | | cancer | digestive | stomach | |
| therapeutic strategies to inhibit the CCL5/CCR5 axis in different ways in the treatment of Gastric cancer | | cancer | digestive | pancreas | |
| blocking CCR5/CCL5 axis might prove beneficial to prevent metastasis and provide a more therapeutic strategy to control PC progression |
| | |